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Background: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for 
unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous 
smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated 
outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary 
national database.
Methods: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004–2013) 
receiving CT alone or CRT. Patients undergoing resection or not receiving CT were excluded, as were those 
with M1 disease or unknown M classification. Logistic regression analysis ascertained factors associated 
with CRT administration. Kaplan-Meier analysis evaluated overall survival (OS) between both groups. Cox 
proportional hazards modeling assessed variables associated with OS. 
Results: In total, 2,842 patients were analyzed [n=666 (23%) CRT, n=2,176 (77%) CT]. CRT was 
less likely delivered at community centers, in more recent time periods (2009–2013), to older patients, 
and in certain geographic locations. Median OS in the CRT and CT groups were 13.6 vs. 10.5 months, 
respectively (P<0.001). On multivariate analysis, poorer OS was associated with age, male gender, increased 
comorbidities, treatment at a community center, and treatment at earlier time periods (2004–2008) (P<0.05 
for all). Notably, receipt of CRT independently predicted for improved OS (P<0.001). 
Conclusions: As compared to CT alone, CRT was independently associated with improved survival in 
unresected IC. These findings support a randomized trial evaluating this question that is currently accruing.
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Introduction
Despite its rarity in the United States, intrahepatic 
cholangiocarcinoma (IC) is associated with a poor 
prognosis, especially for unresected disease. The National 
Comprehensive Cancer Network (NCCN) offers a category 
1 recommendation of chemotherapy (CT) alone for this 
population (1). Chemoradiotherapy (CRT) is a category 2a 
recommendation, largely owing to no randomized evidence 
to date.
The addition of local therapy for biliary neoplasms 
is appealing and an area of active investigation (2,3). 
Postoperative patterns of recurrence are largely locoregional 
prior to development of distant metastasis; in fact, initial 
failure occurs distantly in just 10–15% of cases (4). 
Locoregional recurrence is also the main cause of tumor-
related mortality in these patients (4). Moreover, numerous 
non-comparative publications have highlighted the safety 
and efficacy of adding radiotherapy (RT) to CT; these have 
allowed for high local control, low toxicity rates, and/or 
numerically prolonged survival (5-12). Many of these studies 
underscore the importance of providing local therapy to 
prevent locoregional tumor progression, which can lead to 
symptomatic worsening and a deterioration in quality of life. 
This comparative study of a large, contemporary national 
database sought to evaluate national practice patterns and 
outcomes of unresected IC receiving CT alone versus 
CRT. Although challenging to assess with single- or multi-
institutional analyses owing to the relative rarity of this 
neoplasm, the National Cancer Data Base (NCDB) provides 
a unique resource with which to address this novel but 
clinically important issue.
Methods
The NCDB is a joint project of the Commission on Cancer 
(CoC) of the American College of Surgeons and the 
American Cancer Society, which consists of de-identified 
information regarding tumor characteristics, patient 
demographics, and patient survival for approximately 70% 
of the US population (13). All pertinent cases are reported 
regularly from CoC-accredited centers and compiled into 
a unified dataset, which is then validated. The NCDB 
contains information not included in the Surveillance, 
Epidemiology, and End Results (SEER) database, including 
details regarding use of systemic therapy. The data used 
in the study were derived from a de-identified NCDB file 
(2004–2013). The American College of Surgeons and 
the CoC have not verified and are neither responsible for 
the analytic or statistical methodology employed nor the 
conclusions drawn from these data by the investigators. 
As all patient information in the NCDB database is de-
identified, this study was exempt from institutional review 
board evaluation.
Inclusion criteria for this study were patients with 
newly-diagnosed primary IC. Other biliary neoplasms or 
hepatocellular carcinoma were not included in the assigned 
dataset given by the NCDB. Patients that underwent 
resection (lobectomy, hepatectomy, wedge/segmental 
resection, or surgery not otherwise specified) were excluded. 
Patients with M1 disease, unknown M classification, or in 
situ disease were excluded. Patients without known receipt 
of CT were eliminated (1,14). Those with missing RT status 
were also eliminated, as were those coded as palliative in the 
database. All patients were dichotomized into two groups 
based on receipt of CT alone versus CRT. In accordance 
with the variables in NCDB files, information collected on 
each patient broadly included demographic, clinical, and 
treatment parameters.
All statistical tests were performed with SAS software 
(Version 9.4, Cary, NC, USA); tests were two-sided, with a 
threshold of P<0.05 for statistical significance. Univariable 
and multivariable logistic regression were used to determine 
characteristics associated with receipt of CRT. All initially 
examined variables were considered for inclusion into models 
for stepwise selection (at the 0.05 level), except clinical T 
and N classification owing to the numerous patients with 
missing information. Survival analysis (performed with 
Kaplan-Meier methodology) evaluated overall survival (OS), 
defined as the interval between the date of diagnosis and 
the date of death or censored at last contact. Univariate and 
multivariate Cox proportional hazards modeling evaluated 
predictors of OS, performed with stepwise selection initially 
encompassing all available variables. 
Results
Figure 1 illustrates the patient selection diagram for this 
investigation. In total, 2,842 patients met study criteria 
(Table 1); 666 (23%) patients underwent CRT, and 
2,176 (77%) received CT alone. Following univariable 
assessment, multivariable analysis revealed that patients 
receiving CRT were older, underwent therapy at academic 
centers, and lived farther from the treating facility (P<0.05 
for all). There were also regional differences in CRT 
administration, with decreased use in the Northeast and 
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Figure 1 Patient selection diagram.
National Cancer Data Base 
Intrahepatic biliary cancer cases, 2004-2013 
(n=16,933)
Resection performed or unknown 
(n=3,455)
Metastatic (M1) or unknown 
(n=5,355)
Unknown or no chemotherapy 
(n=4,744)
Unknown radiotherapy status
(n=17)
Palliative care
(n=520)
Study population 
(n=2,842)
Chemotherapy alone
 (n=2,176)
Chemoradiation
 (n=666)
Table 1 Characteristics of the overall cohort and factors associated with receiving chemoradiation
Parameter
Chemo alone 
(N=2,176)
Chemoradiation 
(N=666)
Univariable Multivariable (stepwise)
OR (95% CI) P value OR (95% CI) P value
Age (years)
Median [interquartile range] 65 [56–72] 65 [56–73] 1.00 (0.99–1.01) 0.685 1.01 (1.00–1.02) 0.037
Gender
Male 1,081 (50%) 357 (54%) 1.17 (0.98–1.39) 0.076
Female 1,095 (50%) 309 (46%) REF REF
Race
White 1,845 (85%) 583 (88%) 1.49 (1.04–2.13) 0.020
Black 184 (8%) 39 (6%) REF REF
Other 125 (6%) 39 (6%) 1.47 (0.89–2.42) 0.365
Unknown 22 (1%) 5 (1%) 1.07 (0.38–3.00) 0.702
Charlson Deyo score*
0 1,566 (72%) 523 (78%) REF REF
1 451 (21%) 105 (16%) 0.71 (0.56–0.89) 0.020
≥2 159 (7%) 38 (6%) 0.72 (0.50–1.04) 0.406
Table 1 (continued)
South as compared to the Midwest; CRT was also delivered 
less in more recent time periods (2009–2013 vs. 2004–2008) 
(P<0.05 for all). 
Kaplan-Meier estimates comparing OS in patients that 
underwent CT alone versus CRT are displayed in Figure 2. 
The median follow-up was 10 months (range, 0–114 months), 
the median OS in the respective cohorts was 10.5 [95% 
confidence interval (CI), 10.0–11.5] months and 13.6 (95% CI, 
12.3–15.7) months (P<0.001). 
In all patients, there were several predictors of OS on 
univariate analysis (Table 2). Following multivariate analysis 
(Table 2), factors independently associated with decreased 
OS included advancing age, male gender, increased 
comorbidities, treatment at a community facility, and 
diagnosis in earlier years (P<0.05 for all). Of note, receipt 
of CT alone relative to CRT independently predicted for 
worse OS (hazard ratio 1.38; 95% CI, 1.24–1.54, P<0.001).
Discussion
Our investigation of a large, contemporary national 
database of this relatively rare neoplasm is the largest such 
analysis to date and demonstrates that the addition of RT 
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Table 1 (continued)
Parameter
Chemo alone 
(N=2,176)
Chemoradiation 
(N=666)
Univariable Multivariable (stepwise)
OR (95% CI) P value OR (95% CI) P value
Insurance type
Uninsured 58 (3%) 14 (2%) REF REF
Private 833 (38%) 261 (39%) 1.30 (0.71–2.36) 0.253
Medicaid/other government 163 (7%) 43 (7%) 1.09 (0.56–2.14) 0.693
Medicare 977 (45%) 308 (46%) 1.31 (0.72–2.37) 0.216
Unknown 145 (7%) 40 (6%) 1.14 (0.58–2.26) 0.918
Income (US dollars/year)
<$30,000 319 (15%) 93 (14%) REF REF
$30,000–$34,999 491 (23%) 144 (22%) 1.01 (0.75–1.35) 0.190
$35,000–$45,999 560 (26%) 185 (28%) 1.13 (0.85–1.51) 0.922
≥$46,000 762 (35%) 222 (33%) 1.00 (0.76–1.32) 0.123
Unknown 44 (2%) 22 (3%) 1.72 (0.98–3.01) 0.056
Location
Metro 1,785 (82%) 544 (82%) REF REF
Urban 277 (13%) 73 (11%) 0.86 (0.66–1.14) 0.119
Rural 28 (1%) 9 (1%) 1.05 (0.49–2.25) 0.920
Unknown 86 (4%) 40 (6%) 1.53 (1.04–2.25) 0.053
Percentage of adults in zip code without high school diploma
≥21% 389 (18%) 99 (15%) REF REF
13–20.9% 507 (23%) 151 (23%) 1.17 (0.88–1.56) 0.286
7–12.9% 672 (31%) 218 (33%) 1.27 (0.97–1.67) 0.843
<7% 565 (26%) 176 (26%) 1.22 (0.93–1.62) 0.531
Unknown 43 (2%) 22 (3%) 2.01 (1.15–3.52) 0.039
Facility type
Academic 1,248 (57%) 420 (63%) REF REF REF REF
Community 863 (40%) 223 (34%) 0.77 (0.64–0.92) 0.047 0.78 (0.63–0.96) 0.021
Unknown 65 (3%) 23 (4%) 1.05 (0.65–1.71) 0.461 – –
Facility location
Northeast 500 (23%) 102 (15%) 0.50 (0.38–0.65) <0.001 0.46 (0.34–0.63) <0.001
South 764 (35%) 225 (34%) 0.72 (0.58–0.90) 0.036 0.77 (0.60–0.99) 0.047
Midwest 495 (23%) 202 (30%) REF REF REF REF
West 353 (16%) 114 (17%) 0.79 (0.61–1.03) 0.685 0.84 (0.62–1.14) 0.205
Unknown 64 (3%) 23 (4%) 0.88 (0.53–1.46) 0.452 – –
Distance to treating facility (miles)
Median [interquartile range] 13 [5–37] 15 [6–52] 1.00 (1.00–1.00) <0.001 1.00 (1.00–1.00) 0.002
Year of diagnosis
2004–2008 745 (34%) 290 (44%) REF REF REF REF
2009–2013 1,431 (66%) 376 (57%) 0.67 (0.57–0.81) <0.001 0.58 (0.47–0.71) <0.001
Statistically significant P values (P<0.05) are in italic. Only values included in the final multivariable model are shown. *, The  
Charlson-Deyo index is a weighted score of comorbidities as defined by several medical codes. OR, odds ratio; CI, confidence interval; 
REF, reference.
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Figure 2 Kaplan-Meier overall survival curve comparing those receiving chemotherapy alone versus chemoradiotherapy.
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to CT is independently associated with higher survival in 
unresected IC. These data directly support the currently 
accruing phase III trial of stage III-IV unresectable IC 
receiving gemcitabine/cisplatin with or without tumor-
directed RT, whose primary endpoint is OS (15).
While randomized data are needed for this malignancy, it 
is clear that the retrospective data reported herein may carry 
selection biases similar to several aforementioned studies, 
including potentially performing more aggressive therapy 
in patients that are better able to tolerate multimodality 
therapy or with better risk features. However, it is also 
possible that those receiving CRT were a “higher-risk” 
population with poorer prognostic tumor features and yet 
still experienced a significantly higher OS (16,17). While 
we are not able to compare tumor size between cohorts 
owing to the lack of surgical resection, it is possible that 
local therapy may have been more often delivered to bulky 
disease at higher risk for future symptomatology, or from 
doubt that CT alone could sufficiently control disease 
progression. To this extent, a limitation of this study is the 
NCDB’s lack of information on tumor size, and that the 
T and N classifications were also missing in most patients, 
likely because this cohort consisted of non-operative 
patients. Additionally, because all patients received CT, it 
is unlikely that one group was more “unhealthy” than the 
other, since both cohorts were “fit” enough to receive CT.
Another element that further adds credence to these 
findings is the study design. Although the NCDB records 
RT dose information, we intentionally opted not to utilize 
it as an inclusion/exclusion criterion. Placing a dose 
threshold may have artificially inflated survival for the 
CRT cohort, since only the “healthiest” patients would 
tolerate full-dose RT. Despite evaluating all RT patients, 
including those with suboptimal dose and/or tolerance, the 
CRT cohort still experienced statistically higher OS. Other 
reasons for not evaluating RT dose included existing studies 
utilizing a wide variety of doses (5-12), the NCCN’s lack of 
a single-best recommended dose for unresected tumors (1), 
incomplete NCDB dose reporting in many cases, and the 
overall uncommonness of this malignancy such that further 
limiting patient numbers would not have allowed adequate 
sample sizes for comparative analysis.
An interesting area of ongoing investigation of RT for 
unresected IC is the impact of RT modality. Although 
conventionally-fractionated RT has been historically utilized, 
advances in radiation oncology have involved the application 
of stereotactic body RT (SBRT) (5,8,9,12) and proton beam 
therapy (PBT) (10,18,19). Both allow for high conformality; 
SBRT offers the ability to deliver ablative doses in far fewer 
treatments than conventional fractionation. This is highly 
important for the practical utility of a local therapy modality; 
secondary analyses of prospective data have supported high 
doses per fraction with improved local control and OS (11). 
Additionally, PBT is being actively investigated for 
numerous gastrointestinal neoplasms and may allow the 
maintenance of favorable dosimetric profiles despite large 
irradiated volumes (20). However, because the NCDB 
largely has unknown/missing codes for RT modality, this 
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Table 2 Univariate and multivariate Cox proportional hazards model for overall survival
Parameter
Univariate Multivariate (stepwise)
HR (95% CI) P value HR (95% CI) P value
Age
Continuous variable 1.01 (1.01–1.02) <0.001 1.01 (1.01–1.02) <0.001
Gender
Male 1.11 (1.02–1.21) 0.017 1.13 (1.03–1.24) 0.006
Female REF REF REF REF
Race
White 1.13 (0.95–1.33) 0.164
Black REF REF
Other 0.97 (0.75–1.24) 0.795
Unknown 0.98 (0.60–1.57) 0.918
Charlson Deyo score*
0 REF REF REF REF
1 1.19 (1.06–1.32) 0.002 1.13 (1.01-1.27) 0.030
≥2 1.39 (1.17–1.65) <0.001 1.31 (1.10-1.56) 0.003
Insurance type
Uninsured REF REF
Private 0.77 (0.58–1.03) 0.079
Medicaid/other government 0.79 (0.57–1.10) 0.162
Medicare 0.93 (0.70–1.24) 0.628
Unknown 0.70 (0.50–0.98) 0.038
Income (US dollars/year)
<$30,000 REF REF
$30,000–$34,999 0.91 (0.79–1.06) 0.219
$35,000–$45,999 0.86 (0.75–0.99) 0.039
≥$46,000 0.87 (0.76–1.00) 0.045
Unknown 1.07 (0.81–1.41) 0.625
Location
Metro REF REF
Urban 1.12 (0.99–1.28) 0.082
Rural 1.31 (0.90–1.90) 0.160
Unknown 1.03 (0.84–1.26) 0.797
Percentage of adults in zip code without high school diploma
≥21% REF REF
13–20.9% 1.04 (0.90–1.19) 0.614
7–12.9% 0.99 (0.87–1.13) 0.857
<7% 0.95 (0.83–1.09) 0.505
Unknown 1.19 (0.90–1.57) 0.216
Facility type
Academic REF REF REF REF
Community 1.25 (1.14–1.36) <0.001 1.17 (1.07–1.27) 0.001
Table 2 (continued)
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Table 2 (continued)
Parameter
Univariate Multivariate (stepwise)
HR (95% CI) P value HR (95% CI) P value
Unknown 0.98 (0.75–1.26) 0.853 – –
Facility location
Northeast 1.04 (0.92–1.19) 0.522
South 1.03 (0.92–1.16) 0.615
Midwest REF REF
West 1.08 (0.94–1.24) 0.287
Unknown 0.94 (0.72–1.22) 0.629
Distance to treating facility
Continuous variable 1.00 (1.00–1.00) <0.001
Year of Diagnosis
2004–2008 REF REF REF REF
2009–2013 0.91 (0.83–0.98) 0.034 0.88 (0.80–0.96) 0.004
Treatment group
Chemotherapy alone 1.41 (1.27–1.57) <0.001 1.38 (1.24–1.54) <0.001
Chemoradiation REF REF REF REF
Statistically significant P values are in italic. HR, hazard ratio; CI, confidence interval; REF, reference.
work cannot address this issue further.
Lastly, a recent report from Korea demonstrated that 
delivering combined-modality therapy can allow for tumor 
downsizing in a small proportion of patients, which can 
then facilitate the ability to undergo surgical resection (20). 
Because patients receiving surgery were excluded from this 
work, we also cannot speak to this notion, but it is certainly 
conceivable that well-selected patients may benefit from RT 
so as to allow for resection, making the potential magnitude 
of benefit for RT even greater than what is reported in 
this analysis. However, predicting tumor response is more 
challenging, and hence patient selection for combined-
modality treatment must be more completely addressed in 
future work.
As observed herein, the independent association between 
treatment at an academic center and OS has far-reaching 
implications on patient counseling and management by 
both oncologists and referring providers. Potential causes 
of this finding are not limited to greater multimodality 
coordination, streamlined and thorough diagnostic 
processes, technical expertise, ancillary support staff for 
close clinical monitoring, and the availability of salvage 
therapies or clinical trials. Nevertheless, this finding 
may impact any case of unresected IC and could warrant 
revisions in patterns of patient education.
Although the NCDB provides a unique platform 
with which to study this important clinical question, this 
investigation is not without shortcomings, as described 
elsewhere (21-43). First, NCDB studies are inherently 
retrospective, with selection biases and lack of several 
endpoints such as locoregional control or cancer-specific 
survival. Second, although we excluded palliative care 
patients (based on the NCDB variable), definitions of 
this variable are subject to interpretation and bias. Third, 
as mentioned extensively above, the NCDB does not 
keep track of several other factors, including CT details, 
performance/functional status, RT field design/techniques/
volumes. Furthermore, information on T/N-classification 
and tumor size is largely missing and was hence not able 
to be analyzed. Additionally, the NCDB does not allow for 
an assessment of subsequent lines of treatment (e.g., re-
irradiation, further systemic and/or targeted therapy), which 
could also influence OS. 
Conclusions
This is the largest study to date evaluating CRT versus 
CT alone for unresectable IC. Administration of CRT 
independently predicted for improved survival. However, 
causation is not implied, and an ongoing phase III study will 
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provide definitive evidence regarding this issue.
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